Mefloquine    (DrugBank: Mefloquine)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
25進行性多巣性白質脳症7
46悪性関節リウマチ1

25. 進行性多巣性白質脳症 [臨床試験数:23,薬物数:33(DrugBank:20),標的遺伝子数:7,標的パスウェイ数:36
Searched query = "Progressive multifocal leukoencephalopathy", "PML", "Leukoencephalopathy, progressive multifocal"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
7 / 23 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000022151
2016/04/3030/04/2016The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathyThe efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy - The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathymefloquine is to be taken orally 275mg for 3days then 275mg weekly for 6 manthsDepartment of Neurology, Shimane University HospitalNULLComplete: follow-up complete20years-oldNot applicableMale and Female5Not selectedJapan
2JPRN-UMIN000023752
2016/04/1424/08/2016Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance progressive multifocal leukoencephalopathyOral mefloquine hydrochloride 275mg once a day at first 3 days.
Since second week, 275mg in each week oral intake until 6 months
Nagoya City UniversityNULLComplete: follow-up completeNot applicableNot applicableMale and Female1Not applicableJapan
3EUCTR2008-001314-24-IT
(EUCTR)
15/01/200919/03/2009A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) - NDA Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) - ND Progressive Multifocal Leukoencephalopathy (PML)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy
Trade Name: Lariam
INN or Proposed INN: Mefloquine
BIOGEN IDEC LTDNULLNot RecruitingFemale: yes
Male: yes
40United Kingdom;France;Spain;Italy
4EUCTR2008-001314-24-GB
(EUCTR)
02/01/200928/05/2008A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) Progressive Multifocal Leukoencephalopathy (PML)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy
Trade Name: Lariam
Product Name: Mefloquine
Product Code: 111JC101
INN or Proposed INN: MEFLOQUINE
Biogen Idec LtdNULLNot RecruitingFemale: yes
Male: yes
60United Kingdom;France;Spain;Italy
5NCT00746941
(ClinicalTrials.gov)
January 20093/9/2008Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML)Progressive Multifocal LeukoencephalopathyDrug: mefloquineBiogenElan PharmaceuticalsTerminated18 Years75 YearsAll37Phase 1;Phase 2United States;Brazil;Germany;Italy;Spain;Australia;France;Puerto Rico;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2008-001314-24-ES
(EUCTR)
19/11/200811/07/2008A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP) Progressive Multifocal Leukoencephalopathy (PML)Leucoencefalopatía Multifocal Progresiva (LMP)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy
Trade Name: Lariam
Product Name: Mefloquine
Product Code: 111JC101
INN or Proposed INN: MEFLOQUINE
Biogen Idec LtdNULLNot RecruitingFemale: yes
Male: yes
40United Kingdom;France;Spain;Italy
7EUCTR2008-001314-24-FR
(EUCTR)
22/10/200823/07/2008A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) Progressive Multifocal Leukoencephalopathy (PML)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy
Trade Name: Lariam
Product Name: Mefloquine
Product Code: 111JC101
INN or Proposed INN: MEFLOQUINE
Biogen Idec LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40United Kingdom;France;Spain;Italy

46. 悪性関節リウマチ [臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 4,183 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-002421-31-DE
(EUCTR)
20/10/200503/11/2005A phase II randomised, double-blind, multicenter, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of 3 strengths of AD 452 in adult subjects with active rheumatoid arthritis who are currently taking methotrexate. - Efficacy, safety and tolerability of AD 452 in patients wih RAA phase II randomised, double-blind, multicenter, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of 3 strengths of AD 452 in adult subjects with active rheumatoid arthritis who are currently taking methotrexate. - Efficacy, safety and tolerability of AD 452 in patients wih RA The purpose of this clinical trial is to evaluate the clinical efficacy, safety and tolerability of three doses of AD 452 in comparison with placebo in the treatment of subjects with active rheumatoid arthritis.
MedDRA version: 7.0;Level: PT;Classification code 10039073
Product Name: AD 452
INN or Proposed INN: (+) isomer of racemic mefloquine
Other descriptive name: (+)erythromefloquine
Product Name: AD 452
INN or Proposed INN: (+) isomer of racemic mefloquine
Other descriptive name: (+) erythromefloquine
Product Name: AD 452
INN or Proposed INN: (+) isomer or racemic mefloquine
Other descriptive name: (+) erythromefloquine
Arakis Ltd.NULLNot RecruitingFemale: yes
Male: yes
292Phase 2United Kingdom;Germany